Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03728309 · ClinicalTrials.gov registry record · NA
JUVÉDERM® VOLITE™ XC for Cheek Skin Smoothness
A NA study of Skin Smoothness of the Cheeks, sponsored by Allergan.
- Completed
- Registry status
- NA
- Development phase
- 209
- Enrollment target
- 14
- Study locations
NCT03728309 is a NA study of Skin Smoothness of the Cheeks that has completed, run by Allergan. The registered enrollment target is 209 participants. The trial reports 14 study locations across 10 states.
The verdict
NCT03728309, a NA study of Skin Smoothness of the Cheeks, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- NA
- Development phase
- 209 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a pivotal study to collect safety and effectiveness data on JUVÉDERM VOLITE™ XC for improvement in skin smoothness of the cheeks in order to support FDA product approval.
Conditions Studied
Interventions
- DEVICE JUVÉDERM VOLITE™ XC
Study Locations (14)
California
- Kathleen L. Behr M.D. Inc /ID# 236170 - Fresno
- Dermatology Research Associates /ID# 237649 - Los Angeles
- Ava MD - Santa Monica
- Art of Skin MD - Solana Beach
Massachusetts
- Skincare Physicians /ID# 235383 - Chestnut Hill
- Dermatology PartnersInc. /ID# 234946 - Wellesley
Florida
- Skin Research Institute LLC - Coral Gables
Illinois
- Advanced Dermatology /ID# 234879 - Lincolnshire
Maryland
- Facial Plastic Surgery Center /ID# 234876 - Baltimore
New York
- Dermatology and Laser Surgery Center of New York /ID# 234571 - New York
North Carolina
- Dermatology Laser and Vein Specialists of Carolinas /ID# 236169 - Charlotte
South Carolina
- Clinical Research Center of the Carolinas /ID# 236488 - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2018-11-09 |
| Est. Completion | 2020-07-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03728309
The ClinicalTrials.gov registry entry for NCT03728309 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Skin Smoothness of the Cheeks appearing as the primary indexed condition, and to 1 intervention - of which JUVÉDERM VOLITE™ XC is the first listed.
NCT03728309 reports 14 study locations spanning 10 distinct geographic areas - top geographies include California, Massachusetts, Florida.
Frequently Asked Questions
What is clinical trial NCT03728309 about?
NCT03728309 is a clinical study titled "JUVÉDERM® VOLITE™ XC for Cheek Skin Smoothness". This is a pivotal study to collect safety and effectiveness data on JUVÉDERM VOLITE™ XC for improvement in skin smoothness of the cheeks in order to support FDA product approval.
What is the current status of trial NCT03728309?
This trial is currently completed. It is a NA study. The enrollment target is 209 participants. The study started on 2018-11-09. Estimated completion is 2020-07-17.
What conditions does trial NCT03728309 study?
This clinical trial studies the following conditions: Skin Smoothness of the Cheeks.
What interventions are being tested in trial NCT03728309?
The interventions under investigation include: JUVÉDERM VOLITE™ XC (DEVICE).
Who is sponsoring clinical trial NCT03728309?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03728309 being conducted?
This trial has 14 study locations across California, Florida, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.